文献速递头颈甲状腺与浅表US

甲状腺结节细针穿刺活检指征:基于评分与基于模式的风险分层系统比较

Fine needle aspiration biopsy indications for thyroid nodules: compare a point-based risk stratification system with a pattern-based risk stratification system.
PubMed 文献 · Eur Radiol · 2019-02-04

该回顾性研究纳入2016年5月至2017年12月918例患者的1001个甲状腺结节,比较ACR TI-RADS与ATA指南评估甲状腺结节及推荐细针穿刺活检的诊断性能与可靠性。ACR TI-RADS的AUC显著高于ATA指南(0.935 vs 0.884,p<0.001),且ACR TI-RADS不必要FNAB率低于ATA指南(40.5% vs 61.5%)。结论认为ACR TI-RADS在鉴别良恶性结节和推荐FNAB方面均优于ATA指南。

要点

  • ACR TI-RADS鉴别甲状腺结节良恶性的AUC为0.935,显著高于ATA指南的0.884(p<0.001)。
  • ACR TI-RADS的不必要FNAB率为40.5%,低于ATA指南的61.5%。
  • ACR TI-RADS推荐FNAB的恶性活检率(91.3%)与ATA指南(97.4%)均较高,但ACR TI-RADS活检恶性产出率更高(59.5% vs 38.5%)。

核心结论

  • ACR TI-RADS在鉴别甲状腺结节良恶性方面比ATA指南更准确,在推荐甲状腺结节进行FNAB方面比ATA指南更可靠。

研究设计与样本

  • 回顾性研究,纳入2016年5月至2017年12月共918例患者的1001个连续甲状腺结节,回顾分析超声特征(成分、回声、形态、边缘、强回声灶及大小)并分别按ACR TI-RADS与ATA指南分类,比较两种系统评估结节及推荐FNAB的诊断性能与可靠性。

诊断标准与关键数值

  • ACR TI-RADS:敏感度96.7%,特异度77.3%,PPV 73.3%,NPV 97.3%,准确率84.9%。
  • ATA指南:敏感度99.2%,特异度16.1%,PPV 43.2%,NPV 97.0%,准确率48.7%。
  • 活检恶性产出率:ACR TI-RADS 59.5% vs ATA指南 38.5%;活检恶性率:ACR TI-RADS 91.3% vs ATA指南 97.4%;不必要FNAB率:ACR TI-RADS 40.5% vs ATA指南 61.5%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aim to compare the diagnostic performance to assess thyroid nodules and reliability for recommending fine needle aspiration biopsy (FNAB) between American College of Radiology thyroid image reporting and data system (ACR TI-RADS) and American Thyroid Association (ATA) guidelines.

METHODS: In total, this retrospective study included 1001 consecutive thyroid nodules in 918 patients from May 2016 to December 2017. US features of the thyroid nodules, including composition, echogenicity, shape, margins, echogenic foci, and size, were reviewed and were classified according to ACR TI-RADS and ATA guidelines, respectively. The diagnostic performance to assess thyroid nodules and reliability for recommending fine needle aspiration biopsy were compared between ACR TI-RADS and ATA guidelines.

RESULTS: Of the 1001 thyroid nodules, 609 (60.8%) were benign and 392 (39.2%) were malignant. The sensitivity, specificity, PPV, NPV, and accuracy were 96.7%, 77.3%, 73.3%, 97.3%, and 84.9%, respectively, for ACR TI-RADS and 99.2%, 16.1%, 43.2%, 97.0%, and 48.7%, respectively, for ATA guidelines. AUC of ACR TI-RADS was significantly greater than ATA guidelines (0.935 (0.918, 0.949) vs 0.884 (0.862, 0.903), p < 0.001). Biopsy yield of malignancy, biopsy rate of malignancy, and unnecessary FNAB rate were 59.5%, 91.3%, and 40.5%, respectively, for ACR TI-RDS and 38.5%, 97.4%, and 61.5%, respectively, for ATA guidelines.

CONCLUSIONS: ACR TI-RADS was more accurate than ATA guidelines for differentiating malignant thyroid nodules from benign nodules and more reliable than ATA guidelines for recommending thyroid nodules for FNAB.

KEY POINTS: • Malignant risk of thyroid nodules can be stratified by ultrasound. • American College of Radiology guidelines were more accurate for differentiating malignant thyroid nodules from benign nodules. • American College of Radiology guidelines were more reliable for recommending thyroid nodules for biopsy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ruan JL, Yang HY, Liu RB, et al. Fine needle aspiration biopsy indications for thyroid nodules: compare a point-based risk stratification system with a pattern-based risk stratification system. Eur Radiol. 2019. PMID: 30715590. doi:10.1007/s00330-018-5992-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。